Project Grant R01AG095776
Award Date 9/1/25
Completion Date 5/31/30
Dollars Obligated $840K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $848,286 to the University of South Florida to conduct research on the role of N6-methyladenosine (m6A) RNA modifications in Alzheimer's disease (AD). The key objectives are to: 1) Create a high-resolution map of m6A sites in the brains of older adults, 2) Identify specific m6A alterations associated with AD and its clinical/pathological features, and 3) Elucidate how m6A dysregulation may...
- This Project Grant award titled "Epitranscriptomic Regulation of Microglia in Alzheimer's Disease" was provided by the National Institute on Aging (CFDA 93.866 - Aging Research) to Duke University. The $509,413 grant, awarded on September 15, 2025, will support research to understand the role of epitranscriptomic regulation, specifically the m6A modification, in controlling microglial function and its contribution to Alzheimer's disease pathogenesis. The project aims to elucidate how...
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $805,573 project grant to The Regents of the University of California, San Francisco to investigate the impact of m6A RNA modifications in Alzheimer's disease and related tauopathies. The grant will support research to uncover changes in m6A RNA modifications and their functional consequences in post-mortem brain tissue from subjects with Alzheimer's disease and other tauopathies,...
- This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to elucidate the role of RNA modification, specifically N6-methyladenosine (m6A), in the pathogenesis of Alzheimer's disease (AD) and related tauopathies. The total award amount is $745,092 over the project period from January 1, 2025 to November 30, 2029. The key objectives are to: 1) decode the epitranscriptomic profiles impacted by tau pathology using m6A DART-seq; 2) determine the role of RNA...
- This federal Project Grant award for $528,876, provided by the National Institute on Aging (CFDA 93.866 Aging Research), supports research to investigate the cis- and trans-genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease (AD) and AD-related dementias (ADRD). The key goals of the project are to: Estimate genome-wide cis- and trans-acting quantitative trait loci (QTLs) effects for transcriptome-wide genes and proteome-wide proteins across 4 brain...
- The National Institute on Aging (NIA) awarded a $442,357 Project Grant under the Aging Research program (CFDA 93.866) to the Research Foundation of the City University of New York (RFCUNY) on December 15, 2024. The grant aims to elucidate the molecular mechanisms that give rise to functionally neurodegenerative microglia, the brain's primary innate immune cells, which have been implicated as major determinants of Alzheimer's disease (AD) risk. The research will leverage novel mouse models and...
- The National Institute on Aging (NIA), under the Department of Health and Human Services, awarded a $852,273 Project Grant titled "Genetic Mapping of M6A and Pseudouridine RNA Modifications in the Aging Human Brain and Their Impact on Alzheimer's Disease" to The Trustees of Columbia University in the City of New York. The project, which runs from September 1, 2025 to May 31, 2030, aims to investigate the role of RNA modifications in Alzheimer's disease through an innovative integration...
- This $745,765 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to the Icahn School of Medicine at Mount Sinai (ISMMS) in New York aims to investigate the effects of Alzheimer's disease (AD) risk genes and aging on human microglia activity and lipid metabolism. The key focus is on understanding how genetic variants associated with increased AD risk or longevity may impact microglia's ability to clear cholesterol/lipid-rich cellular debris, a critical...
- This federal Project Grant award of $2,316,710 from the National Institute on Aging (CFDA 93.866 Aging Research) aims to develop magnetogenetic techniques for manipulating the activity of specific brain cell types implicated in the onset and progression of Alzheimer's disease (AD). The research will focus on using a magnetogenetic tool called FERIC (Ferritin Iron Redistribution to Ion Channels) in combination with enhancer AAV vectors to non-invasively control the activity of AD-vulnerable...